Overview

Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.
Phase:
Phase 1
Details
Lead Sponsor:
Arbor Pharmaceuticals, Inc.
Treatments:
Hydralazine
Isosorbide
Isosorbide Dinitrate
Isosorbide-5-mononitrate